These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 30378405)
21. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. Bruix J; Tak WY; Gasbarrini A; Santoro A; Colombo M; Lim HY; Mazzaferro V; Wiest R; Reig M; Wagner A; Bolondi L Eur J Cancer; 2013 Nov; 49(16):3412-9. PubMed ID: 23809766 [TBL] [Abstract][Full Text] [Related]
22. A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17. Yeh CN; Chen MH; Chen YY; Yang CY; Yen CC; Tzen CY; Chen LT; Chen JS Oncotarget; 2017 Jul; 8(27):44121-44130. PubMed ID: 28487491 [TBL] [Abstract][Full Text] [Related]
23. Posterior reversible encephalopathy syndrome with essential thrombocythemia: A case report. Zhang Y; Lu Z; Li Y; Wu J; Liu T; Xie X; He X; Zeng Y Medicine (Baltimore); 2019 Aug; 98(34):e16759. PubMed ID: 31441849 [TBL] [Abstract][Full Text] [Related]
25. Posterior reversible encephalopathy syndrome in children with kidney disease. Gavrilovici C; Miron I; Voroneanu L; Bădărau S; Stârcea M Int Urol Nephrol; 2017 Oct; 49(10):1793-1800. PubMed ID: 28836059 [TBL] [Abstract][Full Text] [Related]
26. Atypical posterior reversible encephalopathy syndrome associated with Lenvatinib therapy in a patient with metastatic thyroid cancer-A case report. Abhishek M; Renuka A; Ujjwal A; Amit C; Vijay P; Vanita N; Nandini M; Kumar P Cancer Rep (Hoboken); 2022 Sep; 5(9):e1605. PubMed ID: 35243821 [TBL] [Abstract][Full Text] [Related]
33. A case of posterior reversible encephalopathy syndrome associated with acute pancreatitis and chronic alcoholism. Baek HS; Lee SJ Gen Hosp Psychiatry; 2015; 37(2):192.e3-5. PubMed ID: 25578790 [TBL] [Abstract][Full Text] [Related]
34. Posterior Reversible Encephalopathy Syndrome as an Overlooked Complication of Induced Hypertension for Cerebral Vasospasm: Systematic Review and Illustrative Case. Muhammad S; Güresir Á; Greschus S; Scorzin J; Vatter H; Güresir E Stroke; 2016 Feb; 47(2):519-22. PubMed ID: 26628389 [TBL] [Abstract][Full Text] [Related]
35. Regorafenib Also Can Cause Osteonecrosis of the Jaw. Antonuzzo L; Lunghi A; Giommoni E; Brugia M; Di Costanzo F J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26857267 [No Abstract] [Full Text] [Related]
36. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors. Crona DJ; Keisler MD; Walko CM Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629 [TBL] [Abstract][Full Text] [Related]
37. Atypical reversible posterior leukoencephalopathy syndrome (RPLS) induced by cediranib in a patient with metastatic rectal cancer. Kim CA; Price-Hiller J; Chu QS; Tankel K; Hennig R; Sawyer MB; Spratlin JL Invest New Drugs; 2014 Oct; 32(5):1036-45. PubMed ID: 24853074 [TBL] [Abstract][Full Text] [Related]
38. Posterior reversible encephalopathy syndrome in cancer patients: a single institution retrospective study. Kamiya-Matsuoka C; Paker AM; Chi L; Youssef A; Tummala S; Loghin ME J Neurooncol; 2016 May; 128(1):75-84. PubMed ID: 26900076 [TBL] [Abstract][Full Text] [Related]
39. Regorafenib for treatment of hepatocellular carcinoma. Sherman M Hepatology; 2018 Mar; 67(3):1162-1165. PubMed ID: 29059458 [No Abstract] [Full Text] [Related]
40. Neuroimaging features in posterior reversible encephalopathy syndrome: A pictorial review. Ollivier M; Bertrand A; Clarençon F; Gerber S; Deltour S; Domont F; Trunet S; Dormont D; Leclercq D J Neurol Sci; 2017 Feb; 373():188-200. PubMed ID: 28131186 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]